Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors
Journal for ImmunoTherapy of Cancer · 2025-04 · 13 (4) · e010767
DOI: 10.1136/jitc-2024-010767 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 01.04.2025. Verfasst von Yenan Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Pharmaceutical Biotechnology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Receptors, Immunologic, Tumor-Associated Macrophages, Adenoviridae, Oncolytic Viruses. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, the State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing University.
Abstract (Originalsprache)
Background
The pleiotropic roles of tumor-associated macrophages (TAMs) render them attractive targets in antitumor drug development. CD47/SIRPα (signal regulatory protein alpha) and CD24/Siglec-10 (sialic acid-binding immunoglobulin-like lectin 10) signaling pathways have been found to suppress macrophage phagocytosis of malignant cells. Systemic blockade of CD47/SIRPα has shown severe side effects. Intratumoral delivery of a CD47 inhibitor by oncolytic viruses (OVs) may circumvent this hurdle.
Methods
To identify the characteristics of recombinant adenovirus (AdV)-SIRPα/Siglec-10, we conducted CCK8 assay, quantitative PCR, western blot, competitive binding assay, in vitro cytotoxicity assay, ELISA and phagocytosis assay. We investigated the antitumor immune responses of AdV-SIRPα/Siglec-10 using flow cytometry, various tumor-bearing mouse models, humanized tumor-bearing mouse models, immune cell depletion, RNA sequencing, and in vitro T cell activation assay.
Results
Here, we developed a novel AdV encoding a fusion protein composed of the extracellular domains of murine or human SIRPα and Siglec-10 (SIRPα/Siglec-10), termed AdV-mSS or AdV-huSS. The SIRPα/Siglec-10 was effectively secreted by cells infected with AdV-mSS and functioned as a dual blocker of CD47 and CD24, thereby significantly enhancing macrophage phagocytosis. In a series of tumor models, including subcutaneous and ascitic H22 hepatocellular carcinoma (HCC), subcutaneous Hepa1-6 HCC, MC38 colorectal carcinoma, and Lewis lung carcinoma, AdV-mSS treatment markedly enhanced antitumor efficacy. Mechanistically, AdV-mSS reprogrammed TAMs toward an antitumor phenotype and enhanced the expression of major histocompatibility complex (MHC)-I/II, promoting CD8+T cell proliferation and activation. Depletion of either macrophages or CD8+T cells abrogated the antitumor efficacy of AdV-mSS. Similarly, in a humanized LM3 HCC mouse model, AdV-huSS significantly inhibited tumor growth and prolonged survival.
Conclusions
Dual SIRPα/Siglec-10 inhibitor delivered intratumorally by AdV not only reinvigorated the TAM-CD8+T cell axis but also potentially reduced the risk of off-target effects. Further investigation of AdV-huSS in patients with cancer is warranted in the near future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Pharmaceutical Biotechnology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China.
- Jiangsu Key Laboratory of Molecular Medicine, Nanjing University Medical School, Nanjing, Jiangsu, China.
- State Key Laboratory of Pharmaceutical Biotechnology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China wjw@nju.edu.cn dongjie@nju.edu.cn.
- Department of Pathogen Biology, Nantong University School of Medicine, Nantong, Jiangsu, China.
Förderung
- National Natural Science Foundation of China
- the State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University
- Nanjing University
- Practice Innovation Program of Jiangsu Province
Zitieren
APA
Zhang, Y., He, B., Zou, P., Wu, M., Wei, M., Xu, C., Dong, J., & Wei, J. (2025). Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors. Journal for ImmunoTherapy of Cancer, 13(4), e010767. https://doi.org/10.1136/jitc-2024-010767
Vancouver
Zhang Y, He B, Zou P, Wu M, Wei M, Xu C, et al. Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors. Journal for ImmunoTherapy of Cancer. 2025;13(4):e010767. doi:10.1136/jitc-2024-010767
BibTeX
@article{Zhang2025,
author = {Zhang, Yenan and He, Bohao and Zou, Peng and Wu, Mengdi and Wei, Min and Xu, Chuning and Dong, Jie and Wei, Jiwu},
title = {Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
volume = {13},
number = {4},
pages = {e010767},
doi = {10.1136/jitc-2024-010767}
}
EUVIMED